Comparison of a frozen human foreskin fibroblast cell assay to an enzyme immunoassay and toxigenic culture for the detection of toxigenic Clostridium difficile  by Strachan, Alastair J. et al.
Diagnostic Microbiology and Infectious Disease 75 (2013) 42–45
Contents lists available at SciVerse ScienceDirect
Diagnostic Microbiology and Infectious Disease
j ourna l homepage: www.e lsev ie r.com/ locate /d iagmicrob ioComparison of a frozen human foreskin ﬁbroblast cell assay to an enzyme
immunoassay and toxigenic culture for the detection of toxigenic
Clostridium difﬁcile☆ ,☆☆ ,★
Alastair J. Strachan a,⁎, Natalie E. Evans a, O. Martin Williams b, Robert C. Spencer b,
Rosemary Greenwood c, Chris J. Probert d
a Department of Clinical Sciences, University of Bristol, Bristol, UK
b Health Protection Agency Microbiology Services, Bristol, Bristol, UK
c Research Design Service–South West, University Hospital Bristol NHS Foundation Trust, Bristol, UK
d Department of Gastroenterology, University of Liverpool, Liverpool, UK☆ The authors have no conﬂicts of interest and have m
to the production of this manuscript.
☆☆ Alastair Strachan and Natalie Evans contributed to
manuscript. Rosemary Greenwood contributed to th
Williams and Chris Probert contributed to the study
reviewing the manuscript. Robert Spencer was invol
manuscript.
★ Address where research was conducted: Health Pr
Services, Level 8, Bristol Royal Inﬁrmary, Marlborough S
⁎ Corresponding author. Tel.: +44-117-3422514; fax
E-mail address: ally.strachan@bristol.ac.uk (A.J. Strac
0732-8893 © 2013 Elsevier Inc.
http://dx.doi.org/10.1016/j.diagmicrobio.2012.09.013
Open access under CC BYa b s t r a c ta r t i c l e i n f oArticle history:
Received 19 June 2012
Received in revised form 12 September 2012
Accepted 20 September 2012





CytotoxinThis study set out to validate the Hs27 ReadyCell assay (RCCNA) as an alternative CCNA method compared
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Open access under CC BY license.1. Introduction
Clostridium difﬁcile is the most common cause of nosocomial
colitis, with symptoms ranging from asymptomatic carriage to severe
diarrhoea, pseudomembranous colitis, toxic megacolon, and death
(Williams and Spencer, 2009). These symptoms are the result of the
toxins excreted by the bacteria; non–toxin-producing strains of the
bacteria are nonpathogenic (Williams and Spencer, 2009). A fast and
accurate method for the diagnosis of the infection is required to
improve patient care and reduce the risk of transmission. Since 2007,
the prevalence of C. difﬁcile infection (CDI) has decreased in the UK
(Health Protection Agency, 2011), although it is still rising in other
countries (Crobach et al., 2009).The choice of laboratory test can have a signiﬁcant impact on the
accuracy of a C. difﬁcile diagnosis (Crobach et al., 2009; Carroll, 2011;
Planche and Wilcox, 2011). Cell cytotoxin neutralisation assays
(CCNA) are recommended as the gold standard (GS) for detecting
C. difﬁcile toxin B in a laboratory environment (Crobach et al., 2009;
Carroll, 2011; Planche and Wilcox, 2011), but the drawbacks of using
this method including the 48-h turnaround time, cell line mainte-
nance, and technical expertise have led to many laboratories choosing
enzyme immunoassays (EIA) as their diagnostic method; EIA have a
shorter turnaround times and cost less than CCNA. EIAs are commonly
used to detect toxins A and B, but it has been reported that their ability
to accurately diagnose a toxigenic C. difﬁcile infection can be
substandard (Carroll, 2011).
A new commercial method of cytotoxin testing using Hs27
Human Foreskin Fibroblast (HFF) ReadyCells (Diagnostic Hybrids,
Athens, OH, USA) and requiring no cell line maintenance was
recently introduced to overcome the problems of the EIA and
previous CCNA testing methods. These cells are an alternative to the
commonly used Vero cells whose performance has been well
documented (Eastwood et al., 2009; Novak Weekley et al., 2010).
Although the merits of CCNA testing for C. difﬁcile diagnosis are also
known, there is little published experience of the new method. A
recent review highlighted the availability of commercially available
frozen HFF cells but noted their use requires validation (Planche
and Wilcox, 2011).
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as an alternative CCNA method and to compare their diagnostic
capability for toxigenic C. difﬁcile against a commonly used commer-
cial EIA method and toxigenic culture (TC) reference standard.
2. Materials and methods
Routine clinical samples sent to the laboratory were tested for C.
difﬁcile if they matched stool form types 5 to 7 on the Bristol Stool
Scale (Lewis and Heaton, 1997) and met any of the following patient
criteria: aged ≥65 years, taking or had recently taken antibiotics, a
hospital inpatient, immunosuppressed, requested by the patient's
clinician. From those who met these criteria, samples were selected
that were fresh (b24 h since being collected), N5 mL in volume, from
patients aged ≥18 years old who had diarrhoea for N24 h.
2.1. Enzyme immunoassay
The Premier C. difﬁcile Toxin A & B microwell EIA (Meridian
Bioscience, Cincinnati, OH, USA) was used in accordance with the
Health Protection Agency (HPA) standard operating procedures on
the DS2 analyser (Launch Diagnostics, Kent, UK) by HPA staff. Optical
densities (OD) were determined using the manufacturer's guidelines
at 450 and 630 nm; a positive result was determined by an OD ≥0.1
and a negative result by an OD b0.1.
2.2. Cell cytotoxin neutralization assay
Human foreskin ﬁbroblast Hs27 ReadyCells (Diagnostic Hybrids)
were used for the CCNA. One millilitre of stool was frozen on receipt
and testing performed in batches. Samples were defrosted and added
to 3 mL of specimen diluent (dilution 1:4) and centrifuged at 3500 × g
for 10 min. The supernatant was removed and passed through a 0.45-
micron sterile syringe ﬁlter (Whatman, Dassel, Germany). Two sterile
1.5-mL Eppendorf tubes were prepared for each sample, 1 containing
0.2 mL of specimen diluent, the other 0.2 mL of antitoxin control, with
0.2 mL specimen ﬁltrate added to both (dilution 1:8) and left to
incubate at room temperature for 30 min. The HFF ReadyCells were
removed from storage at−70 °C and defrosted in the ReadyCell heat
block (Diagnostic Hybrids) for 4 min. The cells' maintenance media
was removed and 0.8mL of fresh RefeedMedium (Diagnostic Hybrids,
Athens, OH, USA) added to each cell vial. With a sterile pipette tip,
0.2 mL of the specimen ﬁltrate and 0.2 mL of the antitoxin control
solution were added to separate RCCNA vials. All vials were incubated
at 37 °C with 5% CO2 for a maximum of 48 h. Cell lines were examined
at 24 and 48 h of incubation using an inverted microscope, ×10
magniﬁcation, for signs of cytopathic effect (CPE). A positive result
was deﬁned by ≥50% cell lysis with no evidence of cytotoxicity in the
relevant antitoxin control vial.
2.2.1. Repeat samples
Samples where no clear result could be determined (both
specimen and control vial displaying CPE, destruction of cell
monolayer) were repeated with titrations of 1:8, 1:16, and 1:32
added to separate RCCNA vials and incubated as above.
2.3. Toxigenic culture
All stool samples were processed for TC according to a protocol
modiﬁed from the one set out by Eastwoodet al. (2009). 0.5mL of stool
was added to 0.5 mL of industrial methylated spirit or at a ratio of 1:1
and left to ‘shock’ at room temperature for 30 min. One loop full of the
shock was inoculated onto Brazier's agar (Oxoid, Cambridge, UK) and
incubated in anaerobic conditions for 48 h. Suspected C. difﬁcile
colonies were inoculated onto fastidious anaerobic agar (Oxoid) and
reincubated for a further 48 h. Positive C. difﬁcile culture wasdetermined by meeting all the following: yellow/green colonies
under UV ﬂuorescence, a positive latex agglutination (Microgen
Bioproducts, Camberley, UK), and the characteristic horse barn
odour. Positive C. difﬁcile cultures were run on the DS2 analyser for
CDT EIA testing as outlined above.
2.4. Statistical analysis
Statistical analysis was performed using the IBM SPSS 19 software
package (SPSS, Chicago, IL, USA) to provide kappa values and 95%
conﬁdence intervals. Sensitivities, speciﬁcities, positive predictive
values (PPVs), and negative predictive values (NPVs) were also
derived for each test method.
3. Results
A total of 860 samples were identiﬁed from those submitted to the
HPA microbiology laboratories from 2 hospital trusts (University
Hospital Bristol NHS Foundation Trust and Royal United Hospital
Bath) over a 30-week period. The prevalence of C. difﬁcile amongst
these cases of diarrhoea was 10.9% with EIA, 11.4% with TC, and 11.9%
with CCNA.
The results for comparing the 3 toxigenic CDI diagnosis methods
are presented in Table 1. The EIA and RCCNA were compared against
one another using the TC as the gold standard (GS) reference method
to compare and evaluate their results. RCCNA performed much better
than EIA when using TC as a GS, with sensitivities of 90.8% (CI 83.3–
95.7) and 78.6% (CI 69.1–81.2), respectively. There was only a slight
difference in speciﬁcity with 98.3% (CI 97.1–99.0) for the RCCNA, only
slightly higher than 97.8% (CI 96.5–98.7). RCCNA was better at
identifying a true-negative result with a NPV of 98.8% (CI 97.8–99.5).
The false-negative rate was 9.2% (4.3–16.7) for RCCNA, compared to a
much higher 21.4% [13.8-30.9] for EIA. The EIA false-positive rate of
2.2% (1.3–3.5) was only 0.5% higher than the recorded level of 1.7%
(0.9–2.9) for the RCCNA. PPVs were higher for the RCCNA (87.3%
[79.2–93.0]) than for the EIA (81.9% [72.6–89.0]).
Kappa values for EIA andRCCNAwere 0.777 and0.876, respectively,
showing a higher level of repeatability for the RCCNA when TC is used
as GS.When the reliability of eachmethodwas evaluated, no statistical
signiﬁcance could be found between EIA and TC (P = 0.627), EIA and
RCCNA (0.200), and RCCNA against TC (0.523).
A total of 3.3% (28/860) of RCCNA samples included in the study
were repeated. Eight-two percent (23/28) were repeated due to
‘bunching’ of the cell monolayer, and a further 18% (5/28) showed CPE
in both vials. Samples which needed repeating incurred a further cost
of approx £27.00 per sample.
Fifteen percent of positive C. difﬁcile cultures were negative on the
EIA component of the TC algorithm and therefore resulted as negative
for TC. It is possible that these cultures contained nontoxigenic C. difﬁcile
strains or that the Toxin A & B EIA result was a false negative.
4. Discussion
There is still much debate regarding the best method for the
diagnosis of toxigenic C. difﬁcile, with the need for an accurate and
relevant diagnosis often compromised by the requirement of a rapid
result. A key advantage of the CCNA test method has been its
sensitivity to detect small quantities (1 pg) of C. difﬁcile toxin (Lyerly
et al., 1988). Due to factors such as reductions in available technical
expertise, costs, and cell line maintenance, CCNA methods have not
been adopted by most clinical laboratories for the diagnosis of the
disease. A recent survey found that only 3.6% of English National
Health Service laboratories used the CCNAmethod for the detection of
CDI (Goldenberg and French, 2011).
The RCCNA is a new commercially available method of cytotoxin
testing, designed to test directly from stool and overcome the
Table 1
Comparison of performance results for the RCCNA and EIA method compared to a toxigenic culture reference standard.
Test
methoda
No. of specimens Performance (95% Conﬁdence Interval)
Positive Negative Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%) False-positive rate (%) False-negative rate (%)
TC 98 762
EIA 94 766 78.6 (69.1–86.2) 97.8 (96.5–98.7) 81.9 (72.6–89.0) 97.3 (95.7–98.2) 2.2 (1.3–3.5) 21.4 (13.8–30.9)
RCCNA 102 758 90.8 (83.3–95.7) 98.3 (97.1–99.0) 87.3 (79.2–93.0) 98.8 (97.8–99.5) 1.7 (0.9–2.9) 9.2 (4.3–16.7)
a TC = Toxigenic culture; EIA = enzyme immunoassay; RCCNA = Hs27 ReadyCell cytotoxin cell neutralisation assay.
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writing this report, no peer-reviewed literature could be found to
have examined the validity of the RCCNA as a method of diagnosing
toxigenic CDI.
We found the RCCNA method to have a high level of both
sensitivity and speciﬁcity when compared to the EIA and TC. Against
the commonly used EIA, RCCNA had a higher level of sensitivity (90.8%
versus 78.6%) and similar speciﬁcity (98.3% versus 97.8%) as well as
better scores for PPV (87.3% versus 81.9%) and NPV (98.8% to 97.3%),
suggesting it is a more accurate method for CDI diagnosis. It must be
noted that no signiﬁcant difference could be found between the 2 test
methods. The percentage of samples diagnosed by the RCCNA that
were considered to be false negatives (9.2%) were lower than that by
the EIA (21.4%) although both scores indicate an objectionable
number of missed cases in a clinical setting. False-positive rates for
both the RCCNA and EIA were muchmore acceptable at 1.7% and 2.2%,
respectively. Unlike TC, RCCNA and EIA methods detect toxin levels
from the stool and not from the culture. It has been argued therefore
that TC detects the presence of toxigenic C. difﬁcile strains in the
patient but not whether they are pathogenic (Planche and Wilcox,
2011). This may have caused the high false-positive rates for both the
RCCNA and EIA when compared to TC.
Previous studies using HFF cells have performed the test using
microtitre trays and not the RCCNA. Stamper et al. (2009) recorded a
sensitivity of 67.2% and a speciﬁcity of 99.1% compared to toxigenic
culture. Reller et al. (2007) found the sensitivity rate of CCNA using
HFF cells after a glutamate dehydrogenase (GDH) screen to be 77%.
Another study has noted higher sensitivity levels. Aldeen et al. (2000)
used HFF cells for CCNA recording a sensitivity of 97% and a speciﬁcity
of 100% compared to a Toxin A/B ELISA. Other studies using Vero cells
have recorded sensitivities and speciﬁcities of 86.4% and 99.2%,
respectively (Eastwood et al., 2009). One study rated the sensitivity
and speciﬁcity levels of Vero cells at 83.1% and 96.7%, respectively
(Novak Weekley et al., 2010), although this was after both a GDH and
an EIA screen.
CCNA is considered by some to be the GS for the detection of
toxigenic CDI. RCCNA compared favorably to the reference method of
toxigenic culturewhich is also advocated as a GS (Delmee et al., 2005).
Other research comparing C. difﬁcile diagnostic methods has reported
much lower sensitivities for CCNA compared to TC (Tenover et al.,
2010). Our reduced positive rates for TC could be due to the use of EIA
as the toxin detection component of the algorithm (Carroll, 2011; She
et al., 2009). The RCCNA does have the capability to be the toxigenic
detection component of a TC algorithm, although it was only used
with direct-from-stool samples in this study.
EIA alone appeared to miss approx. 20% of cases, with a sensitivity
of approx. 80% compared to the other approaches. The speciﬁcity and
NPV of the EIAwere comparable and competitive with the other 2. She
et al. (2009) compared the Premier Toxin A & B EIA to the CCNA
method using HFF cells in microtitre wells and TC. They recorded
higher sensitivity levels for the EIA (87.1%) than those recorded in this
study but suggest that the EIA has a low reproducibility level and
could give a high number of false-negative results. Planche et al.
(2008) found the Meridian Premier EIA to have higher levels of
sensitivity (95%) and speciﬁcity (97%). In their study, Planche et al.also highlighted the impact the prevalence of a disease can have on
the PPV of a diagnostic method deﬁning an acceptable test as onewith
a sensitivity of at least 90% and a false-positive rate of 3% or less. The
RCCNA was therefore an acceptable method for detecting toxigenic
CDI according to these guidelines. A difference of 5.4% in PPV between
the RCCNA and the EIA is likely to be the result of the 1% difference in
CDI prevalence recorded in our study.
CCNA was the cheapest of the 3 diagnostic methods with a cost of
approximately £9.00 per sample. The EIA was slightly more expensive
(~£11.00 per sample), although a result could be provided within an
hour. RCCNA required up to 48 h for a conﬁrmatory negative result;
however, some positive cell lysing was observed from 2 to 6 h of
incubation. Although seen by some as the GS and used as the
referencemethod for this study, TCwas themost expensivemethod at
approx. £21.00 per sample. TC result turnaround time was also the
longest at 96 h for a positive result.
Themost common reason for repeating a specimens CCNA test was
the phenomena of destruction to the cell monolayer or ‘bunching’,
which occurred to both the specimen and control cell vials, suggesting
it to be specimen speciﬁc and not handler error. Although 3.3% of
samples were repeated for CCNA, this method still proved more cost-
effective than using the EIA, which required no repeat testing. The
reasons for the ‘bunching’ phenomena were unknown by the kit
supplier or manufacturer and it was beyond the scope of this project
to determine its cause, which increased the time to ﬁnd a true result
and processing costs.
Recent guidelines by the British Government's Department of
Health advocate the use of a 2-step algorithm for the detection of
toxigenic CDI and conﬁrmed that EIA was not suitable as a
standalone diagnostic test and should be preceded by a screening
test of either GDH antigen EIA or nucleic acid ampliﬁcation
(Department of Health, 2012). This highlights the fact that CCNA
is not considered a suitable method as part of a 2-step algorithm for
the diagnosis of toxigenic C. difﬁcile. Some laboratories have
adopted polymerase chain reaction (PCR) within their testing
algorithms for CDI, which aids the diagnosis of strain types and
can highlight potentially hypervirulent strains such as PCR ribotype
027. A limitation to our study was that ribotyping of all positive
C. difﬁcile cultures to determine strain type was not carried out. A
further limitation to the study was the inability to collect clinical
details including antibiotic usage for all patients.
The Hs27 HFF ReadyCells are an easy-to-use and sensitive CCNA
method for the detection of toxigenic C. difﬁcile directly from stool.
They do not require the technical expertise of cell line maintenance
and are more cost-effective than other CCNA methods and some
commonly used commercial laboratory tests. However, the turn-
around times and ability to require repeat testing make it an
unsuitable method to be used in a clinical laboratory setting.
However, the RCCNA's ability to maintain GS sensitivities suggests
that it would be a viable method in a nonclinical laboratory setting,
such as a reference laboratory. Further research is required to
understand the mechanisms that cause damage to the cell monolayer
and increase the rate of repeat testing. Additionally, future studies of
this algorithm would beneﬁt from further clinical and diagnostic
details such as antibiotic usage and C. difﬁcile strain type.
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